08:24 AM EST, 11/08/2024 (MT Newswires) -- Akero Therapeutics ( AKRO ) reported a Q3 net loss Friday of $1.05 per share, widening from a loss of $0.71 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.94 per share.

The company did not report any revenue for the quarter.

As of Sept. 30, Akero said it had $787.1 million in cash, cash equivalents and short and long-term marketable securities, and expected it could fund operations through H2 2027.